Brianna Lindsay

Brianna Lindsay

Auto-generated profile, based on publicly available information

Brianna Lindsay

Department of Biology, University of Pennsylvania, Philadelphia, PA, 19104, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2016 in Clinical Infectious Diseases
Verified
Journal Article
Open access
SGSuzanne M. Garland
Suzanne M. Garland
SKSusanne K. Kjaer
Susanne K. Kjaer
NMNubia Muñoz
Nubia Muñoz
SBStan L. Block
Stan L. Block
DBDarron R. Brown
Darron R. Brown
CVChristine Velicer
Christine Velicer
Prophylactic human papillomavirus (HPV) vaccination programs constitute major public health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) vaccination on HPV infection and disease. PubMed and Embase were systematically searched for peer-reviewed articles from January 2007 through February 2016 to identify observational studies reporting the impact or effectiveness of 4vHPV vaccination on infection, anogenital warts, and cervical cancer or precancerous lesions. Over the last decade, the impact of HPV vaccination in real-world settings has become increasingly evident, especially among girls vaccinated before HPV exposure in countries with high vaccine uptake. Maximal reductions of approximately 90% for HPV 6/11/16/18 infection, approximately 90% for genital warts, approximately 45% for low-grade cytological cervical abnormalities, and approximately 85% for high-grade histologically proven cervical abnormalities have been reported. The full public health potential of HPV vaccination is not yet realized. HPV-related disease remains a significant source of morbidity and mortality in developing and developed nations, underscoring the need for HPV vaccination programs with high population coverage.

27 June 2014 in Genome Biology
Verified
Journal Article
Open access
PDF file
MPMihai Pop
Mihai Pop
AWAlan W Walker
Alan W Walker
JPJoseph Paulson
Joseph Paulson
BLBrianna Lindsay
Brianna Lindsay
MAMartin Antonio
Martin Antonio
OSO Colin Stine
O Colin Stine
Background: Diarrheal diseases continue to contribute significantly to morbidity and mortality in infants and young children in developing countries. There is an urgent need to better understand the contributions of novel, potentially uncultured, diarrheal pathogens to severe diarrheal disease, as well as distortions in normal gut microbiota composition that might facilitate severe disease. Results: We use high throughput 16S rRNA gene sequencing to compare fecal microbiota composition in children under five years of age who have been diagnosed with moderate to severe diarrhea (MSD) with the microbiota from diarrhea-free controls. Our study includes 992 children from four low-income countries in West and East Africa, and Southeast Asia. Known pathogens, as well as bacteria currently not considered as important diarrhea-causing pathogens, are positively associated with MSD, and these include Escherichia/Shigella, and Granulicatella species, and Streptococcus mitis/pneumoniae groups. In both cases and controls, there tend to be distinct negative correlations between facultative anaerobic lineages and obligate anaerobic lineages. Overall genus-level microbiota composition exhibit a shift in controls from low to high levels of Prevotella and in MSD cases from high to low levels of Escherichia/Shigella in younger versus older children; however, there was significant variation among many genera by both site and age. Conclusions: Our findings expand the current understanding of microbiota-associated diarrhea pathogenicity in young children from developing countries. Our findings are necessarily based on correlative analyses and must be further validated through epidemiological and molecular techniques.

1 June 2013 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
BLBrianna Lindsay
Brianna Lindsay
JOJohn B. Ochieng
John B. Ochieng
UIUsman N. Ikumapayi
Usman N. Ikumapayi
ATAliou Toure
Aliou Toure
DADilruba Ahmed
Dilruba Ahmed
OSO. Colin Stine
O. Colin Stine
Estimates of the prevalence ofShigellaspp. are limited by the suboptimal sensitivity of current diagnostic and surveillance methods. We used a quantitative PCR (qPCR) assay to detectShigellain the stool samples of 3,533 children aged 2.9 × 104ipaHcopies. Ninety (10%) specimens were positive by traditional culture forShigella. Individuals with ≥2.9 × 104ipaHcopies have 5.6-times-higher odds of having diarrhea than those with <2.9 × 104ipaHcopies (95% confidence interval, 3.7 to 8.5;P< 0.0001). Nearly identical results were found using an independent set of samples. qPCR detected 155 additional MSD cases with high copy numbers ofipaH, a 90% increase from the 172 cases detected by culture in both samples. Among a subset (n= 2,874) comprising MSD cases and their age-, gender-, and location-matched controls, the fraction of MSD cases that were attributable toShigellainfection increased from 9.6% (n= 129) for culture to 17.6% (n= 262) for qPCR when employing our cutpoint. We suggest that qPCR with a cutpoint of approximately 1.4 × 104ipaHcopies be the new reference standard for the detection and diagnosis of shigellosis in children in low-income countries. The acceptance of this new standard would substantially increase the fraction of MSD cases that are attributable toShigella.

10 December 2018 in Pediatrics
Verified
Journal Article
Closed access
PDF file
BDBrian E. Dixon
Brian E. Dixon
GZGregory D. Zimet
Gregory D. Zimet
SXShan Xiao
Shan Xiao
WTWanzhu Tu
Wanzhu Tu
BLBrianna Lindsay
Brianna Lindsay
SDStephen M. Downs
Stephen M. Downs
BACKGROUND: Human papillomavirus (HPV) infection can lead to serious health issues and remains the most common sexually transmitted infection. Despite availability of effective vaccines, HPV vaccination rates are suboptimal. METHODS: In a cluster randomized trial, an intervention used to target parents of adolescents (11–17 years) eligible for a dose of HPV vaccine, was tested in pediatric clinics part of an urban health system. Parents watched a digital video outlining the risks and benefits of vaccine using a tablet in the examination room. The primary outcome was change in HPV vaccine status 2 weeks after the clinic visit. An intention-to-treat analysis for the primary outcome used generalized estimating equations to accommodate the potential cluster effect of clinics. RESULTS: A total of 1596 eligible adolescents were observed during the 7-month trial. One-third of adolescents visited an intervention clinic. Adolescents who attended an intervention clinic were more likely to be younger (11–12 years) than those who attended a control clinic (72.4% vs 49.8%; P < .001). No differences in race or sex were observed. The proportion of adolescents with an observed change in vaccine status was higher for those attending an intervention clinic (64.8%) versus control clinic (50.1%; odds ratio, 1.82; 95% confidence interval, 1.47–2.25; P < .001). Adolescents whose parents watched the video had a 3-times greater odds of receiving a dose of the HPV vaccine (78.0%; odds ratio, 3.07; 95% confidence interval, 1.47–6.42; P = .003). CONCLUSIONS: Educational interventions delivered within a clinical setting hold promise to improve vaccination behaviors.

8 June 2016 in BMC Genomics
Verified
Journal Article
Open access
PDF file
MPMihai Pop
Mihai Pop
JPJoseph N. Paulson
Joseph N. Paulson
SCSubhra Chakraborty
Subhra Chakraborty
IAIrina Astrovskaya
Irina Astrovskaya
BLBrianna R. Lindsay
Brianna R. Lindsay
OSO. Colin Stine
O. Colin Stine
Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea in inhabitants from low-income countries and in visitors to these countries. The impact of the human intestinal microbiota on the initiation and progression of ETEC diarrhea is not yet well understood. We used 16S rRNA (ribosomal RNA) gene sequencing to study changes in the fecal microbiota of 12 volunteers during a human challenge study with ETEC (H10407) and subsequent treatment with ciprofloxacin. Five subjects developed severe diarrhea and seven experienced few or no symptoms. Diarrheal symptoms were associated with high concentrations of fecal E. coli as measured by quantitative culture, quantitative PCR, and normalized number of 16S rRNA gene sequences. Large changes in other members of the microbiota varied greatly from individual to individual, whether or not diarrhea occurred. Nonetheless the variation within an individual was small compared to variation between individuals. Ciprofloxacin treatment reorganized microbiota populations; however, the original structure was largely restored at one and three month follow-up visits. Symptomatic ETEC infections, but not asymptomatic infections, were associated with high fecal concentrations of E. coli. Both infection and ciprofloxacin treatment caused variable changes in other bacteria that generally reverted to baseline levels after three months.

29 April 2016 in Archives of Osteoporosis
Verified
Journal Article
Open access
PDF file
BLBrianna R. Lindsay
Brianna R. Lindsay
TOTemitope Olufade
Temitope Olufade
JBJennifer Bauer
Jennifer Bauer
JBJane Babrowicz
Jane Babrowicz
RHRebecca Hahn
Rebecca Hahn
Summary We investigated reasons for non-treatment of osteoporosis and discontinuation of osteoporosis therapy. Barriers to treatment include patients’ preference for alternative treatments and a fear of possible side effects. Side effects are a common reason for treatment discontinuation, and they may be associated with a lack of willingness to restart treatment. Purpose/introduction Osteoporosis patients commonly cite treatment-related side effects, or the fear thereof, as a reason for discontinuing or not initiating anti-osteoporosis medications. The purpose of this study was to investigate, from the patient’s perspective, reasons for (i) non-treatment of osteoporosis and (ii) discontinuation of osteoporosis therapy. Methods This was an internet-based survey of postmenopausal women in the USA who self-reported having been diagnosed with osteoporosis. Respondents were recruited from consumer research panels and received nominal compensation. Results Within the surveyed population (N = 1407), 581 patients were currently being treated, 503 had never been treated, and 323 had previously been treated. Among patients never treated for osteoporosis, the highest ranking reasons for non-treatment were the use of alternative treatments such as over-the-counter vitamins/supplements (57.5 % of respondents) and fear of side effects (43.9 %). Among previously treated patients, frequent reasons for discontinuation included the direction of the physician (41.2 % of respondents), concerns about long-term safety (30.3 %), and the experience of side effects (29.8 %). When asked about their willingness to restart their osteoporosis medication, previously treated patients who were not willing (N = 104) to restart had a higher frequency of experiencing side effects (44.2 versus 20.5 % of those willing; P < 0.001). Conclusions From the osteoporosis patient’s perspective, barriers to prescription treatment include a preference for alternative, non-prescription treatments and a fear of possible side effects. Side effects are one of the most common reasons for discontinuing osteoporosis medications, and they appear to be associated with a lack of willingness to restart treatment.